




## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/001,755	10/24/2001	Peter William Taylor	4-20251/C/MA 2102/PCT/CON

CONFIRMATION NO. 5831

## FORMALITIES LETTER



\*OC000000007229615\*

001095  
THOMAS HOXIE  
NOVARTIS CORPORATION  
PATENT AND TRADEMARK DEPT  
564 MORRIS AVENUE  
SUMMIT, NJ 079011027

Date Mailed: 12/26/2001

## NOTICE TO FILE CORRECTED APPLICATION PAPERS

*Filing Date Granted*

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

- An abstract was not provided for this application. An abstract of the technical disclosure is required under 37 CFR 1.72(b).

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202


PART 2 - COPY TO BE RETURNED WITH RESPONSE

1000755 05270001

03CO

HH

CASE 4-20251C/C1C1/MA2102



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV041586727US  
Express Mail Label Number

February 12, 2002  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1642

TAYLOR ET AL.

APPLICATION NO: 10/001,755

FILED: OCTOBER 24, 2001

FOR: LIPOSOMAL INTERFERON HYBRID COMPOSITION

Assistant Commissioner for Patents  
Washington, DC 20231

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS

Sir:


The Notice to File Corrected Application Papers - Filing Date Granted dated December 26, 2001 (a copy of which is enclosed) has a shortened statutory time set to expire on February 26, 2002.

In response, applicants now submit an abstract of the technical disclosure as required under 37 CFR §1.72(b).

Applicants believe that no fee is required. If a fee is required, the Commissioner is hereby authorized to charge such fees to Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,

Novartis Pharmaceuticals Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6950  
Date: February 12, 2002

  
John D. Thallemer  
Attorney for Applicants  
Reg. No. 34,940

10001755-0212001